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Associations between adherence, 
depressive symptoms and health-related quality 
of life in young adults with cystic fibrosis
K. B. Knudsen1* , T. Pressler2, L. H. Mortensen3, M. Jarden3,4, M. Skov2, A. L. Quittner5, T. Katzenstein1 
and K. A. Boisen6
Abstract 
Background: Cystic fibrosis (CF) is a life shortening disease, however prognosis has improved and the adult popula-
tion is growing. Most adults with cystic fibrosis live independent lives and balance the demands of work and family 
life with a significant treatment burden. The aim of this study was to examine the relationships among treatment 
adherence, symptoms of depression and health-related quality of life (HRQoL) in a population of young adults with 
CF.
Methods: We administered three standardized questionnaires to 67 patients with CF aged 18–30 years; Morisky 
Medication Adherence Scale, Major Depression Inventory, and Cystic Fibrosis Questionnaire-Revised.
Results: There was a response rate of 77 % and a majority of the young adults (84 %) were employed or in an educa-
tion program. Most participants (74 %) reported low adherence to medications. One third (32.8 %) of the participants 
reported symptoms of depression. HRQoL scores were especially low on Vitality and Treatment Burden, and symp-
toms of depression were associated with low HRQoL scores (p < 0.01) with medium to large deficits across on all 
HRQoL domains (Cohen’s d 0.60–1.72) except for the domain treatment burden. High depression symptom scores 
were associated with low adherence (r = −0.412, p < 0.001).
Conclusions: Despite improved physical health, many patients with CF report poor adherence, as well as impaired 
mental wellbeing and HRQoL. Thus, more attention to mental health issues is needed.
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Background
Cystic fibrosis (CF) is a genetic, chronic and fatal disease 
that is often diagnosed early in life. CF is a multi-organ 
disease which primarily affects the pancreas, diges-
tive and pulmonary systems, leading to risk of diabetes, 
malnutrition and chronic pulmonary infections (Spoon-
hower and Davis 2016). From the time of diagnosis until 
death, the treatment regimen is a substantial part of daily 
life. This regimen includes chest physiotherapy, inhala-
tion treatments, oral and intravenous medications. Some 
of the treatments are daily and preventive, while others 
are therapeutic and may be increased during pulmonary 
exacerbations (O’Sullivan and Freedman 2009). Optimi-
zation of medical treatment has improved survival, how-
ever respiratory failure is the main cause of death. Thirty 
years ago, few individuals with CF reached adulthood. 
Today, the average life expectancy for newborns with 
CF is approximately 40 years and is projected to be more 
than 50  years if mortality continues to decrease at the 
rate observed between 2000 and 2010 (MacKenzie et al. 
2014; Ratjen et al. 2015). As a result, there is an increased 
focus on adolescents’ transition into adulthood, as 
well as issues of adherence, mental health and health-
related quality of life (HRQoL) (Quittner et al. 2014a, b; 
Sawicki et  al. 2011). In qualitative studies, young adults 
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have described their lives with CF as a complex balance 
between leading a healthy normal life and feeling differ-
ent from peers due to the burdensome aspects of disease 
management (Jessup and Parkinson 2010; Badlan 2006). 
Many find it challenging to integrate the prescribed treat-
ments into their busy lives, and this has been found to 
affect psychological well-being and HRQoL (Sawicki and 
Goss 2015).
Recently, studies have found poor adherence (Quittner 
et  al. 2014a) and a high prevalence of depression in CF 
populations (Quittner et  al. 2014b; Quittner et  al. 2008; 
Modi et  al. 2011). However, both rates of adherence 
and depression vary between different patient popu-
lations and few studies have included the Danish CF 
population. There is currently no gold standard for meas-
uring adherence to prescribed medications, and rates 
of adherence also vary considerably depending on how 
adherence is measured (Modi et  al. 2006). The Interna-
tional Depression/Anxiety Epidemiological Study of CF 
patients (TIDES), conducted at 154 CF centers in nine 
countries in Europe and USA, reported elevated rates 
of depression for adults across countries, according to 
age, screening measure, and country (Quittner et  al. 
2014b). Overall, 10 % of adolescents and 19 % of adults 
had elevated depression scores, depending on the screen-
ing tool. The Hospital Anxiety and Depression scale 
(HADS) yielded the lowest scores (11 % elevated) versus 
27 % elevated on the Center for Epidemiological Studies 
Depression Scale (CES-D) (Quittner et  al. 2014b). Note 
however, that HADS has been criticized both for a lack 
of sensitivity and a failure to represent the major symp-
toms underlying depression diagnosed using the DSM-
IV or ICD-10 (Cameron et  al. 2008). Denmark was not 
included in TIDES study and thus, the prevalence of 
depression among Danish adolescents and adults with 
CF is not known. It was hypothesized that adults with CF 
who had symptoms of depression would have lower rates 
of adherence and impaired HRQoL. The aim of this study 
was to examine rates of adherence to prescribed treat-
ments, assess symptoms of depression, evaluate HRQoL, 
and test the associations between adherence, depression 
and HRQoL in young adults with CF.
Methods
Material and participants
This was a cross-sectional study using well-validated 
questionnaires administered to young adults aged 
18–30 years with a confirmed diagnosis of cystic fibrosis 
(CF). Participants were recruited from November 2013 
to December 2014 at a specialized, outpatient clinic for 
CF at the Copenhagen University Hospital, Rigshospi-
talet, which is one of the two CF centers in Denmark. 
The Danish CF population consists of 460 people and 
about 300 are followed at Rigshospitalet. Participants 
were recruited during their regular outpatient visit, were 
informed about the study and gave their oral informed 
consent to participate by completing the questionnaires. 
For patients who did not attend the outpatient clinic 
regularly, questionnaires were sent by mail with a self-
addressed, stamped return envelope. The questionnaires 
were provided with an explanatory letter indicating that a 
final consent was inferred from completing and returning 
the questionnaire.
Data on demographic and clinical characteristics were 
extracted from the Danish CF Registry for the entire CF 
population at Rigshospitalet aged 18–30  years, and are 
described as the mean of all measurements obtained in 
2014. Results from lung function tests were obtained 
via chart review, measured by forced expiratory vol-
ume in one second (FEV1). FEV1 values in liters were 
transformed into the percent of predicted (FEV1  %) as 
described by Hankinson et al. (1999).
Patient‑reported outcome measures
Three questionnaires were included and filled out at 
one time point: Morisky Medication Adherence Scale 
(MMAS-8) (Morisky et al. 2008) is a validated self-report 
questionnaire that measures adherence to prescribed 
medications, includes specific medication-taking behav-
iors, and identifies common barriers to poor adherence. 
It is an 8 item test, 7 items rated dichotomously as “yes/
no” responses (0 or 1 point), and one item rated on a 
5-point frequency scale from 0 (never or rarely), 0.25 
(once in a while), 0.50 (sometimes), 0.75 (usually) to 1 
(always) point. A total score on the MMAS ranges from 
0 to 8 points; <6 point indicates low adherence, 6  <  8 
points indicates medium adherence and 8 points reflects 
high adherence (Morisky et al. 2008). MMAS-8 has been 
translated to several languages and many psychometric 
tests of the translated instrument have been performed. 
The scale has demonstrated good sensitivity but only 
moderate internal consistency. The scale has also dem-
onstrated convergent validity with electronic measures 
and is a reliable tool to determine medication adherence 
(Morisky et al. 2008; Arnet et al. 2015).
The Major Depression Inventory (MDI) (Bech et  al. 
2001) is a self-administered instrument that measures 
depressive symptoms. It consists of 10 items that assess 
the ICD-10 and DSM-IV (WHO 1993; APA 1994) symp-
toms of major depressive illness. On a 6-point Likert 
scale, individual items measure how much of the time 
these symptoms have been present during the past 24 h. 
The scale ranges from 0 (symptoms have not been pre-
sent at all) to 5 (symptoms have been present all of the 
time). To fulfill the ICD-10 criteria of moderate to severe 
depression, at least two of the three core symptoms need 
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to be present. The three core symptoms are: depressed 
mood, lack of interest, and lack of energy. Scores range 
from 0 to 50; categorized into ‘No depression’ (0–19 
points), ‘Mild depression’ (20–24 points), ‘Moderate 
depression’ (25–29 points), ‘Severe depression’ (more 
than 29 points) (Bech et al. 2001). Sensitivity and speci-
ficity for DSM-IV has been found to be high for the MDI 
(Olsen et al. 2003). A recent psychometric evaluation of 
the MDI as a depression severity scale confirmed these 
cut-off scores (Bech et  al. 2015). Participants screened 
positive for moderate-severe depression, with a MDI 
score >24, were contacted and offered a consultation with 
a psychologist.
The Cystic Fibrosis Questionnaire-Revised-Teen/Adult 
version (CFQ-R) (Quittner et  al. 2012; Bregnballe et  al. 
2008) is a well-validated, disease-specific HRQoL instru-
ment for individuals with CF ages 14  years and older. 
It has undergone extensive reliability and validity test-
ing and is now considered the “gold standard” measure 
of HRQoL for CF. The CFQ-R assesses demographic 
information (e.g., age, education) and measures twelve 
domains of functioning: Physical Functioning, Vitality, 
Emotional Functioning, Eating Disturbances, Treatment 
Burden, Health Perceptions, Social Functioning, Body 
Image, Role Functioning, Weight, Respiratory Symptoms 
and Digestive Symptoms. Scores are standardized and 
range from 0 to 100, with higher scores indicating better 
quality of life (Quittner et al. 2012).
Statistical analysis
Means and standard deviations were calculated for 
MMAS-8, MDI and CFQ-R, as well as demographic and 
clinical characteristics. Independent t-tests were used to 
determine if there was a difference between participants 
and non-participants. To test how the CFQ-R was asso-
ciated with other characteristics, a one-way multivariate 
analysis of variance (MANOVA) was used to test overall 
differences.
MANOVAs were carried out to test whether independ-
ent variables, such as gender, age group (18–23 years/24–
30  years), marital status (single/partner), level of 
education (lower education/high school/college or uni-
versity), work/education ability versus work/education 
disability, adherence (MMAS score <6/MMAS score ≥6) 
and depression (MDI score <20/MDI score ≥20) were 
associated with the twelve domains of CFQ-R. To control 
for increasing Type I error rate, statistically significant 
MANOVAs were followed up by univariate ANOVAs to 
test domain-specific differences. To estimate the magni-
tude of the association between symptoms of depression, 
ability to work and HRQoL, effect sizes were calculated 
by subtracting the means and dividing the result by the 
pooled standard deviation, resulting in Cohen’s d. Given 
the variable and small sample sizes, calculation of the 
pooled standard deviation was adjusted with weight for 
sample sizes according to Hedges and Olkin (Lakens 
2013).
To determine the strength of the linear relationship 
between MMAS-8 and MDI, we calculated a Pearson 
correlation coefficient. Logistic regression was per-
formed to ascertain the effects of gender, age, civil sta-
tus, level of education, work/education ability related to 
health on adherence (MMAS score <6/MMAS score ≥6) 
and depression (MDI score <20/MDI score ≥20), respec-
tively. Data management and analysis were performed 
using IBM SPSS Statistics version 20. A p value <0.05 was 
considered statistically significant.
Results
During the study period 90 patients aged 18–30  years 
were registered at the Copenhagen CF Center with a 
confirmed CF diagnosis. Three patients lived abroad 
during the study period and were excluded. Among the 
87 eligible patients, 67 completed the questionnaires 
(response rate 77 %). These measures were completed at 
the outpatient clinic by 61 patients; however 12 patients 
who did not attend the clinic regularly received the ques-
tionnaires by mail, and six of these patients returned the 
completed questionnaires. In total, 20 patients did not fill 
in the questionnaires, four refused to participate and 16 
did not respond to inquiries. No significant differences 
were found between the participants versus non-partic-
ipants on any demographic characteristics (see Table 1). 
Most participants (84 %) were employed or in an educa-
tion program and 3  % were unemployed. Nine partici-
pants (13 %) were unable to work or study due to health 
problems.
Adherence
MMAS-8 was completed by 66 participants. Forty-nine 
(74.2 %) scored in the low adherence range (MMAS score 
<6), 12 (18.2  %) had medium adherence (MMAS score 
6 < 8), and five (7.6 %) reported high adherence (MMAS 
score = 8) (Table 2).
Depression
The MDI was completed by all participants. MDI scores 
above 20 indicated symptoms of depression and were 
endorsed by 32.8 % of the participants; 19.4 % expressed 
symptoms of moderate or severe depression (Table  2); 
of these, 77  % had consulted a psychologist or psychia-
trist and/or received antidepressant medication. The 
three remaining participants were contacted and offered 
a consultation with a psychologist, but all claimed to be 
feeling well, and had been sad or worried the day they 
completed the questionnaires. Females were more likely 
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to report more symptoms of depression on the MDI; with 
a female/male OR of 5.1 (95 % CI 1.03–25.3) for moder-
ate/severe depression scores.
Quality of life
The CFQ-R scores across the 12 domains of function-
ing are displayed in Table 3. Vitality and Treatment Bur-
den were the lowest scores (47.1–52.9), indicating poor 
HRQoL; in Body Image and Eating Disturbances were 
the highest scores (77.8–83.4).
Associations between adherence, depression and quality 
of life
To test how the CFQ-R was associated with independent 
variables, such as gender, age, civil status, level of educa-
tion, work/education ability, adherence and depression, 
a one-way multivariate analysis of variance (MANOVA) 
was used to test overall differences. There were statisti-
cally significant difference between CFQ-R and depres-
sive symptoms (p  <  0.01) and work/education ability 
(p < 0.001). Thus, one way ANOVA analyses of the main 
effect of depressive symptoms and work/education abil-
ity were performed and result of the effects on the twelve 
domains are shown in Table 3. Participants who reported 
depression and work/education disability scored signifi-
cantly lower on all domains of the CFQ-R, except Treat-
ment Burden. We found medium to large effects for 
these associations. We found significantly higher HRQoL 
scores for those who had a MDI score <19 (‘No depres-
sion’) compared to those who had a MDI score 20 < 24 
(‘Mild depression’), with similar results for Physical Func-
tioning (p = 0.048), Role Limitations (p = 0.009), Vital-
ity (p = 0.003), Emotional functioning (p = 0.001), Social 
Functioning (p  =  0.02), Health Perception (p  =  0.001) 
and Respiratory Symptoms (p  =  0.03). No associations 
were found between the MMAS-8 scores and the CFQ-R.
Depression and adherence scores were negatively asso-
ciated, increases in MDI scores were associated with 
decreases in MMAS scores (see Fig.  1), indicating that 
symptoms of depression were associated with worse 
adherence, r  =  −0.412, p  <  0.001. Pearson correlations 
were performed with and without the outlier, with no dif-
ference in the results.
An increase in MDI scores was moderately correlated 
with a decrease in MMAS scores, r = −0.412, p < 0.001.
Discussion
In this cross sectional study, which examined rates of 
adherence and depression in relation to HRQoL, we 
found a large number of young adults with CF who 
reported poor adherence, high rates of depression and 
impaired HRQoL.
The MMAS-8 was a useful screening tool, identifying a 
majority of participants with low adherence (74 %). In a 
large national US study, both pediatric and adult patients 
with CF picked up 50 % or fewer prescribed medications 
(Quittner et al. 2014a). A recent systematic review found 
generally poor adherence in patients with CF, with a lack 
of consensus on how to measure adherence (O’Donohoe 
and Fullen 2014). Generally higher rates of adherence 
have been found in studies using self-report measures 
in comparison to more objective measures (e.g., medi-
cation possession ratios, electronic measures) (Modi 
et al. 2006). The MMAS-8 is short (8 questions), easy to 
Table 1 Demographic and  clinical characteristics of  par-
ticipants
CFRD cystic fibrosis related diabetes
a Pseudomonas aeruginosa, Achromobacter xylosoxidans and Burkholderia 
species
b Single status is self-reported and defined as not having a romantic partner
Study participants Non‑participants p value
Number 67 20
Age mean (range) 24.1 (18–30) 22.6 (18–30) 0.09
Females, n (%) 38 (59) 8 (40) 0.20
BMI (kg m2), mean 
(SD)
21.8 (3.6) 21.2 (2.2) 0.40
FEV1 % predicted, 
mean (SD)
72.2 (23) 74 (22) 0.80
FEV1 (≤40 %), n (%) 7 (11) 1 (5)
FEV1 (41–70 %), n (%) 25 (38) 7 (35)
FEV1 (>71 %), n (%) 33 (51) 12 (60) 0.70
Chronic pulmonary 
infectiona, n (%)
40 (62) 10 (50) 0.30
CFRD, n (%) 18 (28) 7 (35) 0.40
Singleb, n (%) 33 (49) NA
Lower education, 
n (%)
21 (31) NA
High school, n (%) 18 (27) NA
College/university, 
n (%)
19 (28) NA
Employed or study-
ing, n (%)
56 (84) NA
Incapacitated to 
work/study, n (%)
9 (13) NA
Table 2 Distribution of MDI and MMAS scores
N (%)
No depression (MDI score 0–19) 45 (67.2)
Mild depression (MDI score 20–24) 9 (13.4)
Moderate depression (MDI score 25–29) 5 (7.5)
Severe depression (MDI score 30–50) 8 (11.9)
Low adherence (MMAS score <6) 49 (74.2)
Medium adherence (MMAS score = 6 < 8) 12 (18.2)
High adherence (MMAS score = 8) 5 (7.6)
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understand, and adaptable for different kinds of medica-
tions (Culig and Leppee 2014). According to the WHO, 
non-adherence among patients with chronic diseases is 
about 50  % in developed countries (Sabaté 2003). Sev-
eral studies have suggested that barriers to CF treatment 
adherence include lack of time, forgetting, social stigma, 
and treatment burden (George et  al. 2010; Bregnballe 
et  al. 2011). Treatment complexity in CF has increased 
over the past decades and high treatment complexity 
scores have been inversely related to Treatment Burden 
on the CFQ-R, indicating that increasing complexity is 
associated with worse perceptions of burden (Sawicki 
et al. 2013). In a qualitative study, patients reported that 
it was a challenge to fit these time-consuming treatments 
into daily life, and some patients were intentionally non-
adherent to permit spontaneity, independence and social 
activities (George et al. 2010).
In the current study, we found low scores on the CFQ-R 
Treatment Burden domain, indicating high perceptions 
of treatment burden across patients, and this effect was 
independent of work ability or symptoms of depres-
sion. We found a moderate negative correlation between 
depression and adherence to treatment. Fidika et  al. 
(2014) reported a decline in lung function (FEV1 % pre-
dicted) in adolescents and adults with CF with elevated 
symptoms of depression in a 2-year observation study. 
Our results support their hypothesis that depressed 
patients may fail to perform their prescribed treatments 
due to mental health problems, such as depression. Thus, 
our findings suggest that treating depression is an impor-
tant target for intervention, and may have positive effects 
Table 3 CFQ-R domain scores in relation to depression scores and employability
a Cohen’s d corrected effect sizes are classified as small (d = 0.2), medium (d = 0.5), large (d = 0.8) and very large (d = 1.3) bValues in italic represent p < 0.05
Total (N = 67) No depression 
(N = 45)
Symptoms 
of depression 
(N = 22)
No depression ver‑
sus depression symp‑
toms
Work/educa‑
tion ability 
(N = 58)
Work/educa‑
tion disability 
(N = 9)
Work/education ability 
versus disability
Mean (SD) Mean (SD) Mean (SD) Effect sizea d p valueb Mean (SD) Mean (SD) Effect sizea d p valueb
Physical func-
tioning
72.8 (27.3) 80.7 (22.6) 56.5 (28.9) −0.98 0.001 79.3 (21.8) 31.0 (22.0) −2.21 0.001 
Role limita-
tions
73.5 (26.0) 81.7 (21.2) 52.6 (27.0) −1.25 <0.001 80.6 (18.2) 22.6 (12.4) −3.09 0.001
Vitality 47.1 (25.3) 58.1 (21.2) 26.4 (15.5) −1.62 <0.001 50.2 (24.4) 27.2 (22.3) −0.93 0.01
Emotional 
functioning
69.3 (20.8) 78.4 (13.8) 50.0 (21.1) −1.72 <0.001 73.0 (18.7) 45.2 (17.6) −1.50 0.001
Social func-
tioning
70.8 (20.7) 77.0 (19.2) 57.7 (14.4) −1.10 <0.001 73.2 (19.7) 55.4 (21.2) −0.90 0.02
Body image 77.8 (23.3) 84.8 (17.1) 61.1 (27.8) −1.12 <0.001 81.3 (20.7) 55.6 (27.8) −1.18 0.002
Eating distur-
bances
83.4 (25.2) 89.4 (20.6) 70.4 (31.7) −0.77 0.007 85.6 (24.1) 69.1 (28.7) −0.67 0.07
Treatment 
burden
52.9 (21.8) 56.1 (21.7) 47.5 (22.5) −0.39 0.17 54.0 (21.2) 45.7 (25.7) −0.38 0.3
Health percep-
tion
55.2 (29.1) 67.7 (23.7) 29.0 (22.9) −1.65 <0.001 60.0 (27.6) 24.7 (19.1) −1.21 0.001
Weight prob-
lems
72.2 (38.6) 78.3 (34.8) 55.6 (42.8) −0.60 0.04 79.5 (32.6) 25.9 (43.4) −1.68 0.001
Respiratory 
symptoms
62.9 (25.0) 69.5 (21.5) 50.0 (26.5) −0.84 0.008 65.8 (23.7) 45.1 (27.0) −0.76 0.02
Digestive 
symptoms
74.0 (24.4) 80.1 (21.2) 62.3 (27.0) −0.77 0.03 73.8 (25.1) 75.3 (20.6) 0.06 0.9
Fig. 1 Correlation between depression scores and adherence scores
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on lung function and other health outcomes. In addition, 
high perceptions of treatment burden and poor adher-
ence should be addressed using systematic, behavioral 
interventions. Brief, behavioral interventions have been 
shown to be most effective in individuals with chronic 
conditions (e.g., HIV) (Gross et al. 2013). These interven-
tions should be tested in the Danish CF population.
In our study, one third of the participants screened 
positive for depression and 19.4  % were in the moder-
ate to severe range. These Danish results are similar to 
the highest rates reported in TIDES study, with rates of 
29  % reported at centers using the CES-D as a screen-
ing tool (Quittner et al. 2014b). In our study, we used the 
MDI, a screening tool used to analyze the prevalence of 
depression in the general population (Olsen et al. 2003). 
Good sensitivity and specificity, as well as responsive-
ness to antidepressant treatments, have been reported 
for the MDI (Bech et al. 2001; Konstantinidis et al. 2011). 
The MDI was not developed for patients with CF and 
there is a risk of identifying false positives. However, it 
is worth noting that the group of participants who had 
symptoms of mild depression, compared to those with 
no symptoms of depression, scored significantly lower on 
HRQoL domains that measure psychosocial functioning. 
Thus, even if the group of patients with mild depression 
symptoms is overestimated, it could be an indication of 
a need for more psychosocial support. These findings 
are in agreement with the consensus statements from 
The International Committee on Mental Health in Cystic 
Fibrosis which recommended that adolescents and adults 
with CF whose depression or anxiety is in the mild range 
should be provided with information about depression 
and anxiety and receive preventive or supportive psycho-
logical interventions (Quittner et al. 2016). All clinically 
elevated scores from screening tools should be followed 
up with a more in-depth clinical interview. Importantly, 
77  % of the 13 participants who reported moderate or 
severe symptoms of depression had already consulted 
a psychologist or psychiatrist and/or received antide-
pressant medication, suggesting that using the MDI as a 
screener provided valid data. Unfortunately, we have no 
information on the length or outcomes of these psycho-
logical or pharmacological treatments. Given that their 
depressive symptoms have persisted, it may be impor-
tant to evaluate evidence-based psychological interven-
tions, tailored specifically to the needs of those with CF 
(Quittner et  al. 2016). Current evidence for psychologi-
cal interventions is insufficient, but cognitive behavioral 
therapy have shown the most promising results accord-
ing to a recent Cochrane review by Goldbeck et al. 2014.
Comparing the CFQ-R results of this study with the 
national, normative data from the US Epidemiologi-
cal Study of CF (ESCF) which had 4679 participants 
(ages ≥14  years) (Quittner et  al. 2012), our scores on 
all domains, except Physical Functioning, Body Image 
and Weight were lower for this cohort of young Danish 
adults. The scores in this study are comparable to those 
reported in a former Danish CF study of patients with 
moderately reduced lung function (FEV1 41–70  % pre-
dicted) (Bregnballe et al. 2008), however more than 51 % 
of the participants in our study had a lung function value 
greater than 70  % of predicted. This study confirms the 
results of prior studies which have found that depression 
is related to worse HRQoL on the CFQ-R. (Havermans 
et al. 2008; Riekert et al. 2007; Yohannes et al. 2012).
Young adults are likely still transitioning to adult roles, 
including starting a career and family, which according to 
Chick and Meleis (1986) may be characterized by disori-
entation, distress, irritability, anxiety and depression. In 
our study, we found markedly reduced HRQoL among 
participants who were not studying or working due to 
health problems. A link between worse lung function and 
reduced HRQoL scores among individuals with CF was 
described by Riekert et al. (2007), however, lung function 
alone does not reflect an accurate picture of a patient’s 
working capabilities (Frangolias et  al. 2003), and in a 
previous study, decreased work capacity was correlated 
with HRQoL, but not with lung function (Targett et  al. 
2014). Having a job clearly has positive effects, such as 
improved financial prosperity, social participation, self-
esteem and psychological well-being (Targett et al. 2014). 
Thus, a combination of inability to work and increasing 
health problems negatively impact HRQoL.
This study includes the majority of young adults with 
CF in Copenhagen, with a high response rate. The 
Copenhagen CF population is generally in a state of 
good health, with relatively high lung function and BMI, 
despite severe CF-mutations (Knudsen et  al. 2015). 
Treatment of Danish patients with CF has been central-
ized since 1962, and these patients are followed at the 
CF center every month and monitored closely. The limi-
tations of this study include the relatively small sample 
size and the use of questionnaires that have not been 
validated in a CF population. The Danish translation of 
MMAS-8 was conducted with a great deal of rigor, but it 
has not been validated in a psychometric study. MMAS-8 
measures ‘total’ adherence, thus differences in adherence 
between types of treatment cannot be assessed. The MDI 
is validated and widely used in Denmark in the general 
population; however it is not a common screening tool 
for depression worldwide. The International Consensus 
Guidelines on Mental Health in CF recommended using 
the PHQ-9 and GAD-7 to screen patients with CF each 
year, beginning at age 12 (Quittner et al. 2016). According 
to Danish law, questionnaire studies can be done without 
the participants’ written consent; however, this implies 
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that individual health data cannot be obtained. Conse-
quently, it was not possible to investigate how FEV1 cor-
related with work disability and HRQOL.
Conclusions
Our study demonstrated that among young adults with 
CF, adherence to prescribed treatments is low, symptoms 
of depression are prevalent and quality of life is impaired. 
Our study confirms that symptoms of depression have 
a significant and negative effect on HRQOL. Finally, we 
demonstrated that the MMAS-8 is a useful tool for meas-
uring adherence among individuals with CF. This study 
supports the recommendations for annual screening of 
depression and anxiety in those with CF ages 12  years 
and older and highlights the mental health needs of 
young adults with CF that need increased attention.
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